Premium
ATS fusion human growth hormone has anti‐ageing effects on old mice
Author(s) -
Lee Saetbyul,
Park Hyunju,
Kim Jongsun
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.686.1
Subject(s) - medicine , in vivo , endocrinology , blood urea nitrogen , chemistry , urea , creatinine , biology , biochemistry , microbiology and biotechnology
Protein aggregation is a major stability problem of therapeutic proteins. Previous studies showed that the ATS (acidic tail of synuclein)‐hGH (human growth hormone) fusion protein was more stable and soluble than wild type hGH. However, bioactivity of the protein was not confirmed in in vivo experiment. We executed a comparative study for hGH and ATS‐hGH in old mice. As shown in preliminary data, we verified that hGH and ATS‐hGH had bio‐activity in cell line experiment. Then, we executed in vivo animal studies, 30 μg/100 μl of hGH and ATS‐hGH were subcutaneously injected to 8 month female mice twice per a week for 14 weeks. As a result, mouse had no change in body weight. However, fat content of abdominal region and triglyceride levels in blood were more significantly reduced in hGH and ATS‐hGH group than those of control group. Most of all, fat content of abdominal region of ATS‐hGH was more reduced than hGH treated group. Also, creatinine was induced, but, urea nitrogen was not increased in blood of hGH and ATS‐hGH group. These results suggest that hGH and ATS‐hGH increased muscle capacity. In addition, immunohistochemistry result through PCNA stanning showed that proliferation of liver cell was increased in hGH and ATS‐hGH group. These result suggest that bioefficacy of ATS‐hGH is better than hGH, particulary effect in reducing the abdominal fat and in increasing the muscle content of old female mice.